Telomir PharmaceuticalsTELO
TELO
About: Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
15% more funds holding
Funds holding: 34 [Q3] → 39 (+5) [Q4]
13% more capital invested
Capital invested by funds: $13.2M [Q3] → $14.9M (+$1.74M) [Q4]
5.06% more ownership
Funds ownership: 6.92% [Q3] → 11.99% (+5.06%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TELO.
Financial journalist opinion
Based on 3 articles about TELO published over the past 30 days
Neutral
Accesswire
1 day ago
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.
Neutral
Accesswire
4 days ago
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species (ROS).
Neutral
Accesswire
3 weeks ago
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
Oxidative stress drives aging and is a key factor in diseases like Alzheimer's, Age-related Macular Degeneration (AMD), cardiovascular diseases, cancer, and diabetes. It also plays a critical role in the progression of viral infections, such as avian influenza (bird flu), by exacerbating inflammation and cellular damage.
Neutral
Accesswire
1 month ago
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)
MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially groundbreaking findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing C.
Neutral
Accesswire
2 months ago
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores Telomir-1 for the treatment of Wilson's disease and other copper related disorders.
Neutral
Accesswire
2 months ago
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential. MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust.
Positive
Benzinga
2 months ago
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
On Tuesday, Telomir Pharmaceuticals, Inc. TELO revealed preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
Neutral
Accesswire
2 months ago
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
MIAMI, FL / ACCESSWIRE / December 3, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus. The study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.
Neutral
Accesswire
3 months ago
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity. Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock.
Neutral
Accesswire
4 months ago
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business Network MIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that the Telomir will be featured on Health Uncensored with Dr. Drew this Sunday, September 29, 2024 at 5:30 PM EST / 2:30 PM PT on Fox Business Network. In this episode, Telomir Pharmaceuticals' Special Advisor, Dr. Michael F.
Charts implemented using Lightweight Charts™